23 results
8-K
EX-99.1
HROW
Harrow Inc
12 Apr 13
Financial Statements and Exhibits
12:00am
This was a non-flare study
Primary Endpoint
WOMAC (pain) week 2
WOMAC (pain ) week 6
WOMAC (pain ) week 4
Secondary Endpoints
Pain Intensity/ relief … = <0.05)
mPP *** (n=250)
Study Mgmt Errors
p = 0.034
© Imprimis Pharmaceuticals, Inc. | A12
Change from baseline
in pain intensity
during daily
424B4
HROW
Harrow Inc
11 Feb 13
Prospectus supplement with pricing info
12:00am
of a treatment effect in this study is further strengthened by a key secondary endpoint (pain intensity recorded three times daily on patient diary … of evidence of a treatment effect in this study is further strengthened by a key secondary endpoint (pain intensity recorded three times daily on patient diary
S-1
lkn1z1
25 Jul 12
IPO registration
12:00am
8-K
EX-99.1
kbedjdu2
17 Jun 10
Regulation FD Disclosure
12:00am
8-K
w4tkbnzdt
27 Jan 10
Other Events
12:00am